ACTRN12617001323314终止4 期
An investigator initiated, multicentre, randomised, double blind placebo controlled study to assess the effectiveness and tolerability of low-dose combination blood pressure-lowering therapy in patients with tension-type headache and borderline elevation of blood pressure - pilot
适应症
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
终止
4 期
Pilot phase for the workplace migraine HeadAche Prevention Project (HAPPy - pilot) to investigate in a double blind randomised factorial trial whether treatment with low-dose combination blood pressure (BP) and cholesterol lowering therapy will reduce migraine compared to standard therapy and placebo.Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)MigraineACTRN12616000937415The George Institute for Global Health180
进行中（未招募）
1 期
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczemaSubjects with nummular eczemaMedDRA version: 20.0Level: PTClassification code 10012431Term: DermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-003162-41-DEKlinikum rechts der Isar, Technische Universität München70
招募中
不适用
Comparison of hemostatic agent to suture in terms of hemostatic function and preservation of ovarian functioDiseases of The genitoruinary systemKCT0005586Seoul National University Hospital90
进行中（未招募）
1 期
Study to test the safety, tolerability and efficacy of UCB7665 in subjects with moderate to severe myasthenia gravis.EUCTR2016-002698-36-CZCB Biopharma SPR42
进行中（未招募）
1 期
Study to test the safety, tolerability and efficacy of UCB7665 in subjects with moderate to severe myasthenia gravis.Moderate to severe myasthenia gravisMedDRA version: 19.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002698-36-ESCB Biopharma SPR42